CareView Communications, Inc. 8-K [crvw-8k_071018.htm]

 

Exhibit 10.43

 

NINTH AMENDMENT TO
NOTE AND WARRANT PURCHASE AGREEMENT

This NINTH AMENDMENT TO NOTE AND WARRANT PURCHASE AGREEMENT, dated as of July
10, 2018 (this “Amendment”), is made by and among CAREVIEW COMMUNICATIONS, INC.,
a Nevada corporation (the “Company”), the HealthCor Parties (as defined below),
and the other holders of Notes identified on the signature pages hereto
(collectively with the HealthCor Parties, and together with their respective
successors and permitted assigns, the “Investors”).

WITNESSETH:

WHEREAS, the Company, HealthCor Partners Fund, L.P. (“HealthCor Partners”),
HealthCor Hybrid Offshore Master Fund, L.P. (“HealthCor Hybrid” and, together
with HealthCor Partners, the “HealthCor Parties”) and certain additional
investors that purchased additional Notes and additional Warrants on February
17, 2015 (the “2015 Investors”) and on February 23, 2018 (the “2018 Investors”)
are parties to that certain Note and Warrant Purchase Agreement, dated as of
April 21, 2011 (as amended from time to time, including without limitation
pursuant to that certain Note and Warrant Amendment Agreement dated December 30,
2011, that certain Second Amendment to Note and Warrant Purchase Agreement dated
January 31, 2012, that certain Third Amendment to Note and Warrant Purchase
Agreement dated August 20, 2013, that certain Fourth Amendment to Note and
Warrant Purchase Agreement dated January 16, 2014, that certain Fifth Amendment
to Note and Warrant Purchase Agreement dated December 15, 2014, that certain
Sixth Amendment to Note and Warrant Purchase Agreement dated March 31, 2015,
that certain Seventh Amendment to Note and Warrant Purchase Agreement dated June
26, 2015, and that certain Eighth Amendment to Note and Warrant Purchase
Agreement dated February 23, 2018, the “Purchase Agreement”);

WHEREAS, as contemplated by the Purchase Agreement, the Company issued and sold
(a) $20,000,000 initial principal amount of Notes (the “2011 Notes”) and
Warrants to purchase 11,782,859 shares of Common Stock (the “2011 Warrants”) to
the HealthCor Parties on April 21, 2011, (b) $5,000,000 initial principal amount
of Supplemental Closing Notes (the “2012 Notes”) to the HealthCor Parties on
January 31, 2012, (c) $5,000,000 initial principal amount of 2014 Supplemental
Closing Notes and 2014 Supplemental Warrants to purchase 4,000,000 shares of
Common Stock to the HealthCor Parties on January 16, 2014, (d) $6,000,000
initial principal amount of Fifth Amendment Supplemental Closing Notes and Fifth
Amendment Supplemental Warrants to purchase 3,692,308 shares of Common Stock to
HealthCor Partners and the 2015 Investors on February 17, 2015 and (e)
$2,050,000 initial principal amount of Eighth Amendment Supplemental Notes and
Eighth Amendment Supplemental Warrants to purchase 512,500 shares of Common
Stock to the 2018 Investors on February 23, 2018; and

WHEREAS, pursuant to Section 7.9 of the Purchase Agreement and subject to the
terms and conditions contained herein, the parties hereto desire to amend the
Purchase Agreement and the Notes and certain ancillary documents as set forth
herein for the purposes of, among other things, (a) removing the conversion
rights of the 2011 Notes and the 2012 Notes, suspending the accrual of interest
thereon for periods after June 30, 2018, and providing for the potential earlier
repayment thereof subject to certain conditions, including the Company’s senior
debt being repaid in full, being first met; (b) cancelling the Warrants issued
to the HealthCor Parties on April 21, 2011; (c) providing for the seniority of
the 2011 Notes and the 2012 Notes in right of payment over subsequently issued
additional Notes, on the terms outlined in this Amendment; (d) amending the
terms of the 2014 Supplemental Closing Notes, the Fifth Amendment Supplemental
Closing Notes and the Eighth Amendment Supplemental Closing Notes to reflect the
seniority in payment of the 2011 Notes and 2012 Notes; and (e) reducing the
number of shares of Common Stock that the Company must at all times have
authorized and reserved for the purpose of issuance upon conversion of the Notes
and exercise of the Warrants, from at least 120% of the aggregate number of
shares of Common Stock then issuable upon full conversion of the Notes and
exercise of the Warrants to at least 100% of such aggregate number of shares.

  

 

NOW, THEREFORE, in consideration of the mutual promises, representations,
warranties and covenants contained herein and in the Purchase Agreement, which
represent integral components of the transactions contemplated hereby and
thereby and shall be fully enforceable by the parties hereto, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and the Investors mutually agree as follows:

1.       

Definitions. Capitalized terms used in this Amendment but not defined in this
Amendment shall have the meanings ascribed to them in the Purchase Agreement.

2.       

Amendment to Purchase Agreement. Section 5.8 of the Purchase Agreement is hereby
amended and restated in its entirety to read as follows:

“Reservation of Shares. The Company shall take all action necessary to at all
times have authorized, and reserved for the purpose of issuance, not less than
100% of the number of shares of Common Stock issuable upon full conversion of
the Notes and exercise of the Warrants (the “Required Reserve Amount”). If at
any time while any Note and/or Warrant remains outstanding the Company does not
have a sufficient number of authorized and unreserved shares of Common Stock to
satisfy its obligation to reserve the Required Reserve Amount (an “Authorized
Share Failure”), then the Company shall take all action necessary to increase
the Company’s authorized shares of Common Stock to an amount sufficient to allow
the Company to reserve the Required Reserve Amount. Without limiting the
generality of the foregoing sentence, as soon as practicable after the date of
the occurrence of an Authorized Share Failure, but in no event later than
seventy-five (75) days after the occurrence of such Authorized Share Failure,
the Company shall hold a meeting of its stockholders for the approval of an
increase in the number of authorized shares of Common Stock. In connection with
such meeting, the Company shall provide each stockholder with a proxy statement
and shall use its commercially reasonable efforts to solicit its stockholders’
approval of such increase in authorized shares of Common Stock and to cause its
board of directors to recommend to the stockholders that they approve such
proposal.”

3.       

Payment Subordination.

(a)       

Definitions. As used in this section, the following terms shall have the
following meanings:

“Bankruptcy Code” means Title 11 of the United States Code entitled
“Bankruptcy,” as now and hereafter in effect, or any successor statute.

“Debtor Relief Laws” means the Bankruptcy Code, and all other liquidation,
conservatorship, bankruptcy, assignment for the benefit of creditors,
moratorium, rearrangement, receivership, insolvency, reorganization, or similar
debtor relief laws of the United States or other applicable jurisdictions from
time to time in effect and affecting the rights of creditors generally.

“Disposition” means any sale, lease, exchange, transfer or other disposition of
any Collateral.

“Grantor” has the meaning set forth in the Security Agreement.

“Insolvency or Liquidation Proceeding” means:

(i)       

any voluntary or involuntary case or proceeding under the Bankruptcy Code with
respect to the Borrower, Holdings or any Grantor;

 2 

 

(ii)       

any other voluntary or involuntary insolvency, reorganization or bankruptcy case
or proceeding, or any receivership, liquidation, reorganization or other similar
case or proceeding, with respect to the Borrower, Holdings or any Grantor or
with respect to a material portion of its assets;

(iii)       

any liquidation, dissolution, reorganization or winding up of the Borrower,
Holdings or any Grantor, whether voluntary or involuntary and whether or not
involving insolvency or bankruptcy; or

(iv)       

any assignment for the benefit of creditors or any other marshaling of assets
and liabilities of the Borrower, Holdings or any Grantor.

(b)       

Each Investor covenants and agrees, notwithstanding anything to the contrary
contained in the Purchase Agreement or any of the Notes, that the payment of any
and all principal, interest and other obligations under the Notes issued
subsequent to the 2011 Notes and 2012 Notes (collectively, the “Subsequent
Tranche Notes”) shall be subordinate and subject in right and time of payment,
to the extent and in the manner hereinafter set forth, to the payment in full in
cash of all principal, interest and other obligations under the 2011 Notes and
2012 Notes (collectively, the “First Tranche Notes”). Until the date all
principal, interest and other obligations in respect of the First Tranche Notes
have been paid in full in cash, except as set forth in Section 3(c), no Investor
holding Subsequent Tranche Notes shall accept any distribution, whether in cash,
securities or other property, on account of any obligations under the Subsequent
Tranche Notes. For the avoidance of doubt, the “Subsequent Tranche Notes”
include each of the 2014 Supplemental Closing Notes, the Fifth Amendment
Supplemental Closing Notes, the Eighth Amendment Supplemental Closing Notes, and
any additional Notes issued under the Purchase Agreement, as it may be amended
from time to time, after the date of this Amendment.

(c)       

Notwithstanding Section 3(b) of this Amendment, the Investors holding Subsequent
Tranche Notes may receive and retain the following distributions in respect of
the Subsequent Tranche Notes: (i) payment of interest in kind that is
capitalized and added to the outstanding principal amount of the Subsequent
Tranche Notes in accordance with the terms thereof as in effect as of the date
hereof and (ii) the conversion of the Subsequent Tranche Notes into equity
securities of the Company.

(d)       

Until the payment in full in cash of any and all principal, interest and other
obligations under the First Tranche Notes, whether or not any Insolvency or
Liquidation Proceeding has been commenced by or against the Company or any other
Grantor, any payment received by any Investor in respect of the Subsequent
Tranche Notes in contravention of this Amendment shall be segregated and held in
trust and forthwith paid over to HealthCor Partners as the collateral agent, for
the benefit of the Investors holding First Tranche Notes in the same form as
received, with any necessary endorsements or as a court of competent
jurisdiction may otherwise direct. HealthCor Partners, as the collateral agent,
is hereby authorized to make any such endorsements as agent for any Investors.
This authorization is coupled with an interest and is irrevocable until the
payment in full in cash of any and all principal, interest and other obligations
under the First Tranche Notes.

4.       

Exercise of Remedies.

(a)       

Until all principal, interest and other obligations under the First Tranche
Notes have been paid in full in cash:

(i)       

(1) except for non-cash payments permitted by Section 3(c) of this Amendment,
the Investors holding Subsequent Tranche Notes will not take from or for the
account of the Company or any other Grantor, by set-off or in any other manner,
the whole or any part of any moneys which may now or hereafter be owing by the
Company or any other Grantor with respect to the obligations under the
Subsequent Tranche Notes; (2) will not sue for payment of, or initiate or
participate with others in any suit, action or proceeding against the Company or
any other Grantor to (x) enforce payment of or collect the whole or any part of
the obligations under the Subsequent Tranche Notes (which shall include, for the
avoidance of doubt, any demand or collection of payment at maturity), or (y)
commence judicial enforcement of any of the rights and remedies under the
Transaction Documents or applicable law with respect to the obligations under
the Subsequent Tranche Notes; and (3) will not exercise any put option or cause
the Company or any other Grantor to honor any redemption or mandatory prepayment
obligation under any Transaction Document with respect to the obligations under
the Subsequent Tranche Notes;

 3 

 

(ii)       

will not exercise or seek to exercise any remedies with respect to any Lien on
any Collateral (as defined in the Security Agreement) to secure the performance
of the obligations under the Subsequent Tranche Notes or institute any action or
proceeding with respect to such remedies (including any action of foreclosure);

(iii)       

will not contest, protest, object to, or take any action to hinder or delay
(including taking action to commence an involuntary Insolvency or Liquidation
Proceeding) any foreclosure proceeding or action brought by the Investors
holding First Tranche Notes or any other exercise by Investors holding First
Tranche Notes of any rights and remedies relating to the Collateral securing the
obligations under the First Tranche Notes; and

(iv)       

will not object to the forbearance by the Investors holding First Tranche Notes
from bringing or pursuing any foreclosure proceeding or action or any other
exercise of any rights or remedies relating to the Collateral;

provided, that, in the case of clause (iii) above, the security interests
granted to secure the obligations under the Subsequent Tranche Notes shall
attach to any remaining proceeds resulting from actions taken by the holders of
the First Tranche Notes in accordance with this Amendment after application of
such proceeds to pay in full in cash any and all principal, interest and other
obligations under the First Tranche Notes.

(b)       

Until the payment in full in cash of all principal, interest and other
obligations under the First Tranche Notes has occurred, whether or not any
Insolvency or Liquidation Proceeding has been commenced by or against the
Company or any Grantor, the Investors holding First Tranche Notes shall have the
right to enforce rights, exercise remedies (including set off and the right to
credit bid their debt) and make determinations regarding the release,
Disposition, or restrictions with respect to the Collateral without any
consultation with or the consent of any holder of Subsequent Tranche Notes;
provided, that the Lien securing the obligations under the Subsequent Tranche
Notes shall remain on the remaining proceeds of such Collateral released or
disposed of subject to the relative priorities described in Section 3 after
application of such proceeds to the extent necessary to effect the payment in
full in cash of all principal, interest and other obligations under the First
Tranche Notes. In exercising rights and remedies with respect to the Collateral,
the Holders of First Tranche Notes may enforce the provisions of the Transaction
Documents and exercise remedies thereunder, all in such order and in such manner
as they may determine in the exercise of their sole discretion. Such exercise
and enforcement shall include the rights of any agent appointed by them to sell
or otherwise dispose of Collateral upon foreclosure, to incur expenses in
connection with such sale or disposition and to exercise all the rights and
remedies of a secured creditor under the UCC (as defined in the Security
Agreement) and of a secured creditor under the Debtor Relief Laws of any
applicable jurisdiction. In furtherance of the foregoing, and for avoidance of
doubt, until the payment in full in cash of all principal, interest and other
obligations under the First Tranche Notes has occurred, the term “Required
Secured Parties” set forth in the Security Agreement shall be deemed to mean the
holders of more than 50% of the aggregate outstanding principal balance of the
First Tranche Notes.

5.       

Hospital Disposition. In connection with any Hospital Disposition, as such term
is defined in the PDL Subordination Agreement, the Company agrees to use the net
proceeds thereof, after payment of transaction expenses, first, to repay the
Company’s obligations under the PDL Credit Agreement until such obligations are
paid in full; and second, to apply the remaining net proceeds (less up to
$5,000,000 which the Company may retain for working capital purposes) to
repayment of the outstanding Principal and Interest on the Notes, until such
amounts are repaid in full. If the proceeds of any such Hospital Disposition are
insufficient to repay the Company’s obligations under the PDL Credit Agreement
in full, the Company undertakes to the HealthCor Parties that it will use its
commercially reasonable efforts to repay any remaining obligations under the PDL
Credit Agreement as soon as practicable, including without limitation with cash
from operations.

6.       

Cancellation of 2011 Warrants. The Company and the HealthCor Parties hereby
agree that the 2011 Warrants, issued to the HealthCor Parties and dated April
21, 2011, representing the right to purchase an aggregate of 11,782,859 shares
of Common Stock, are hereby cancelled and shall be of no further force and
effect.

 4 

 

7.       

Conditions Precedent. The transactions contemplated by this Amendment shall be
conditioned upon the satisfaction of the following conditions:

(a)       

The execution and delivery by the Company and the HealthCor Parties of Allonge
No. 2 to the 2011 Notes and Allonge No. 2 to the 2012 Notes, in the forms
attached as Exhibits 7(a)(1) and 7(a)(2) hereto, respectively;

(b)       

The execution and delivery by the Company and each holder of the 2014
Supplemental Closing Notes of Allonge No. 2 to the 2014 Supplemental Closing
Notes, in the form attached as Exhibit 7(b) hereto;

(c)       

The execution and delivery by the Company and each holder of the Fifth Amendment
Supplemental Closing Notes of Allonge No. 2 to the Fifth Amendment Supplemental
Closing Notes, in the form attached as Exhibit 7(c) hereto;

(d)       

The execution and delivery by the Company and each holder of the Eighth
Amendment Supplemental Closing Notes of Allonge No. 1 to the Eighth Amendment
Supplemental Closing Notes, in the form attached as Exhibit 7(d) hereto; and

(e)       

The execution and delivery by the Company, CareView Texas, PDL and the Investors
of the Second Amendment to Subordination and Intercreditor Agreement, in the
form attached as Exhibit 7(e) hereto.

8.       

Acknowledgement and Undertaking by Company. The Company agrees and acknowledges
that the transactions described in this Amendment, including without limitation
the cancellation of the 2011 Warrants, are intended to be exempt from Section
16(b) of the Exchange Act to the maximum extent permitted by law including
pursuant to Rule 16b-3 under the Exchange Act and the Commission’s releases and
interpretations, and will, or will cause its successors and assigns to, from
time to time as and when requested by the Investors, execute and deliver, or
cause to be executed and delivered, to the extent it may lawfully do so, all
such documents and instruments and take, or cause to be taken, to the extent it
may lawfully do so, all such further actions as the Investors may reasonably
deem necessary and desirable to facilitate and effect any such exemption. 

9.       

No Further Amendments. Except as amended by this Amendment, the Purchase
Agreement shall remain in full force and effect in accordance with its terms.

10.       

Miscellaneous.

(a)       

Ratification and Confirmation. The Company acknowledges, agrees and confirms
that: (x) the Purchase Agreement and each of the other Transaction Documents, as
amended and otherwise modified by the amendments and other modifications
specifically provided herein or contemplated hereby, are and shall continue to
be in full force and effect and are hereby in all respects ratified and
confirmed; and (y) without limiting the generality of the foregoing clause (x),
all obligations, liabilities and Indebtedness of the Company under the
Transaction Documents, as amended hereby, constitute “Obligations” (as defined
in the Security Agreement) secured by and entitled to the benefits of the
security set forth in the Security Agreement and the IP Security Agreement, and
the liens and security interests granted in favor of the Investors under the
terms of the Security Agreement and the IP Security Agreement are and remain
perfected, effective, enforceable and valid and such liens and security
interests are, in each case, a first priority lien and security interest (except
to the extent otherwise expressly permitted by the Transaction Documents) and
such liens and security interests are hereby in all respects ratified and
confirmed.

(b)       

Expenses. The Company will pay and bear full responsibility for the reasonable
legal fees and other out-of-pocket costs and expenses of the Investors
attributable to the negotiation and consummation of the transactions
contemplated hereby.

 5 

 

(c)       

Further Assurances. The Company shall duly execute and deliver, or cause to be
duly executed and delivered, at its own cost and expense, such further
instruments and documents and to take all such action, in each case as may be
necessary or proper in the reasonable judgment of the Investors to carry out the
provisions and purposes of this Amendment.

(d)       

Survival. The representations, warranties, covenants and agreements made herein
shall survive any investigation made by any party hereto, the execution and
delivery of this Amendment and the closing of the transactions contemplated
hereby.

(e)       

Governing Law. All questions concerning the construction, interpretation and
validity of this Amendment shall be governed by and construed and enforced in
accordance with the domestic laws of the State of Delaware without giving effect
to any choice or conflict of law provision or rule (whether in the State of
Delaware or any other jurisdiction) that would cause the application of the laws
of any jurisdiction other than the State of Delaware. In furtherance of the
foregoing, the internal law of the State of Delaware will control the
interpretation and construction of this Amendment, even if under such
jurisdiction’s choice of law or conflict of law analysis, the substantive law of
some other jurisdiction would ordinarily or necessarily apply.

(f)       

Construction. The Company and the Investors acknowledge that the Company and its
independent counsel and the Investors and their independent counsel have jointly
reviewed and drafted this document, and agree that any rule of construction and
interpretation to the effect that drafting ambiguities are to be resolved
against the drafting party shall not be employed.

(g)       

Counterparts; Facsimile and Electronic Signatures. This Amendment may be
executed in any number of counterparts, and each such counterpart hereof shall
be deemed to be an original instrument, but all such counterparts together shall
constitute but one agreement. Counterpart signatures to this Amendment delivered
by facsimile or other electronic transmission shall be acceptable and binding.

(h)       

Headings. The section and paragraph headings contained in this Amendment are for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Amendment.

[Signature Pages Follow]

 6 

 

IN WITNESS WHEREOF, each of the undersigned has duly executed this Ninth
Amendment to Note and Warrant Purchase Agreement as of the date first written
above.

 

  COMPANY:         CareView Communications, Inc., a Nevada corporation        
By: /s/ Steven G. Johnson   Name: Steven G. Johnson   Title: President

 

 

 

  INVESTORS:         HealthCor Partners Fund, L.P.   By:   HealthCor Partners
Management L.P., as Manager   By:   HealthCor Partners Management, G.P., LLC, as
General Partner         By: /s/ Jeffrey C. Lightcap   Name: Jeffrey C. Lightcap
  Title: Senior Managing Director

 

  Address: HealthCor Partners     1325 Avenue of Americas, 27th Floor     New
York, NY 10019      

 

  HealthCor Hybrid Offshore Master Fund, L.P.   By: HealthCor Hybrid Offshore
G.P., LLC, as General Partner         By:  /s/ Joseph P. Healey   Name: Joseph
P. Healey   Title: Trustee

  Address: HealthCor Partners     1325 Avenue of Americas, 27th Floor     New
York, NY 10019      

 

 

[Signature Page to Ninth Amendment to Note and Warrant Purchase Agreement]

 

 

 

  INVESTORS:       /s/ Allen Wheeler   Allen Wheeler       /s/ Steven Johnson  
Steven Johnson       /s/ Dr. James R. Higgins   Dr. James R. Higgins

 

 

 

[Signature Page to Ninth Amendment to Note and Warrant Purchase Agreement]

 

 

 

  INVESTORS:       Raymond James & Assoc. Inc., not in its corporate capacity
but solely as Custodian of the Individual Retirement Account of Sandra K.
McRee.  Further, all representations, warranties and covenants (including
indemnities) set forth herein are being made by Sandra K. McRee, not Raymond
James & Assoc. Inc.           By: /s/ Marguerite Shoro   Name:   Marguerite
Shoro   Title:   Authorized Signer/Custodian               /s/ Sandra K. McRee  
Sandra K. McRee

 

 

[Signature Page to Ninth Amendment to Note and Warrant Purchase Agreement]

 

 

 

  INVESTORS:       /s/ Stephen Berkley   Stephen Berkley           /s/ Alexandra
Berkley   Alexandra Berkley           /s/ Steven B. Epstein   Steven B. Epstein
          /s/ Deborah L. Epstein   Deborah L. Epstein           /s/ Jason Peter
Epstein   Jason Peter Epstein           /s/ Gregory Harris Epstein   Gregory
Harris Epstein           /s/ David Epstein   David Epstein           /s/ Juliann
Martin   Juliann Martin           /s/ Jason Thompson   Jason Thompson

 

 

  Thompson Family Investments, LLC       By: /s/ Jason Thompson   Name: Jason
Thompson   Title: Manager

 

 

[Signature Page to Ninth Amendment to Note and Warrant Purchase Agreement]

 

 

 

  INVESTORS:       /s/ Irwin Leiber   Irwin Leiber           /s/ Joseph P.
Healey   Joseph P. Healey           /s/ Arthur B. Cohen   Arthur B. Cohen

 

 

  SJ2, LLC           By: /s/ Michael Mashaal   Name:   Michael Mashaal  
Title:   Manager           The Joseph P. Healey 2011 Family Trust           By:
/s/ Joseph L. Dowling   Name: Joseph L. Dowling   Title: Trustee          
Rockwell Holdings I, LLC           By: /s/ Matthew Bluhm   Name: Matthew Bluhm  
Title: Managing Member

 

 

[Signature Page to Ninth Amendment to Note and Warrant Purchase Agreement]

 

 

 

 

  INVESTORS:       PENSCO TRUST COMPANY LLC, not in its corporate capacity but
solely as Custodian of the Individual Retirement Account of Jeffrey C. Lightcap
          By: /s/ Cody Alford   Name: Cody Alford   Title: Authorized Signor

 

 

  /s/ Jeffrey C. Lightcap   Jeffrey C. Lightcap

 

 

  Jeffrey C. Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March
20th, 1997 F/B/O Bradford C. Lightcap           By: /s/ Ira Schwartz   Name: Ira
Schwartz   Title: Trustee           Jeffrey C. Lightcap & Jane Lightcap Minor’s
Present Interest Trust dated March 20th, 1997 F/B/O Brian R. Lightcap          
By: /s/ Ira Schwartz   Name: Ira Schwartz   Title: Trustee           Jeffrey C.
Lightcap & Jane Lightcap Minor’s Present Interest Trust dated March 20th, 1997
F/B/O Megan M. Lightcap           By: /s/ Ira Schwartz   Name: Ira Schwartz  
Title: Trustee

 

 

[Signature Page to Ninth Amendment to Note and Warrant Purchase Agreement]

 

 

 

ACKNOWLEDGED AND AGREED:

 

CareView Communications, Inc., a Texas corporation         By: /s/ Steven G.
Johnson   Name: Steven G. Johnson   Title: President               CareView
Operations, LLC         By: /s/ Steven G. Johnson   Name: Steven G. Johnson  
Title: President  

 

 

[Signature Page to Ninth Amendment to Note and Warrant Purchase Agreement]

 

 

 

Exhibit 7(a)(1)

 

Form of Allonge No. 2 to 2011 Notes

 

 

 

 

Exhibit 7(a)(2)

 

Form of Allonge No. 2 to 2012 Notes

 

 

 

Exhibit 7(b)

 

Form of Allonge No. 2 to 2014 Supplemental Closing Notes

 

 

 

 

Exhibit 7(c)

 

Form of Allonge No. 2 to Fifth Amendment Supplemental Closing Notes

 

 

 

Exhibit 7(d)

 

Form of Allonge No. 1 to Eighth Amendment Supplemental Closing Notes

 

 

 

Exhibit 7(e)

 

Form of Second Amendment to Subordination and Intercreditor Agreement